What is Lifesci Capital’s Forecast for ATXS FY2025 Earnings?

Astria Therapeutics, Inc. (NASDAQ:ATXS) – Stock analysts at Lifesci Capital reduced their FY2025 earnings per share (EPS) estimates for Astria Therapeutics in a research report issued on Tuesday, March 11th. Lifesci Capital analyst S. Slutsky now forecasts that the biotechnology company will earn ($1.97) per share for the year, down from their previous forecast of ($1.95). The consensus estimate for Astria Therapeutics’ current full-year earnings is ($1.65) per share.

Several other research analysts also recently issued reports on ATXS. Wedbush reiterated an “outperform” rating and set a $28.00 price target (up from $27.00) on shares of Astria Therapeutics in a report on Wednesday. JMP Securities started coverage on Astria Therapeutics in a report on Friday, January 31st. They issued an “outperform” rating and a $26.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a report on Tuesday, March 11th. Finally, Citizens Jmp raised shares of Astria Therapeutics to a “strong-buy” rating in a research report on Friday, January 31st. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $26.67.

Astria Therapeutics Stock Performance

Shares of NASDAQ:ATXS opened at $6.45 on Friday. The company has a fifty day moving average of $7.14 and a 200-day moving average of $9.51. The company has a market capitalization of $364.00 million, a PE ratio of -3.09 and a beta of 0.69. Astria Therapeutics has a 52-week low of $5.73 and a 52-week high of $16.90.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.01.

Institutional Trading of Astria Therapeutics

A number of institutional investors have recently bought and sold shares of ATXS. FMR LLC boosted its position in shares of Astria Therapeutics by 29.2% during the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock worth $86,123,000 after purchasing an additional 1,767,714 shares in the last quarter. RA Capital Management L.P. boosted its position in shares of Astria Therapeutics by 1.2% during the 3rd quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock worth $56,208,000 after purchasing an additional 61,457 shares in the last quarter. Vestal Point Capital LP boosted its position in shares of Astria Therapeutics by 4.5% during the 4th quarter. Vestal Point Capital LP now owns 4,180,000 shares of the biotechnology company’s stock worth $37,369,000 after purchasing an additional 180,000 shares in the last quarter. Fcpm Iii Services B.V. bought a new position in shares of Astria Therapeutics during the 4th quarter worth about $25,680,000. Finally, Vanguard Group Inc. boosted its position in shares of Astria Therapeutics by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 2,677,353 shares of the biotechnology company’s stock worth $23,936,000 after purchasing an additional 41,833 shares in the last quarter. Institutional investors own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.